# Neuroendocrine Tumor Research Advances
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/neuroendocrine-tumor-research-advances/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10754 |
| Works | 550 |
## Topic papers all
Showing 15 of 550.
- [One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States](https://scholariq.org/papers/one-hundred-years-after-carcinoid-epidemiology-of-and-prognostic-factors-for/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)
- [Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States](https://scholariq.org/papers/trends-in-the-incidence-prevalence-and-survival-outcomes-in-patients-with/)
- [Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Consensus statement on the pathology of IgG4-related disease](https://scholariq.org/papers/consensus-statement-on-the-pathology-of-igg4-related-disease/)
- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group](https://scholariq.org/papers/placebo-controlled-double-blind-prospective-randomized-study-on-the-effect-of/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors](https://scholariq.org/papers/lanreotide-in-metastatic-enteropancreatic-neuroendocrine-tumors/)
- [Gastroenteropancreatic neuroendocrine tumours](https://scholariq.org/papers/gastroenteropancreatic-neuroendocrine-tumours/)
- [Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011](https://scholariq.org/papers/comprehensive-diagnostic-criteria-for-igg4-related-disease-igg4-rd-2011/)
- [Small-cell lung cancer](https://scholariq.org/papers/small-cell-lung-cancer/)
- [TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system](https://scholariq.org/papers/tnm-staging-of-foregut-neuro-endocrine-tumors-a-consensus-proposal-including-a/)
- [Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011](https://scholariq.org/papers/comprehensive-diagnostic-criteria-for-igg4-related-disease-igg4-rd-2011-2/)
## Topic primary papers
Showing 15 of 301.
- [One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States](https://scholariq.org/papers/one-hundred-years-after-carcinoid-epidemiology-of-and-prognostic-factors-for/)
- [Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States](https://scholariq.org/papers/trends-in-the-incidence-prevalence-and-survival-outcomes-in-patients-with/)
- [Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group](https://scholariq.org/papers/placebo-controlled-double-blind-prospective-randomized-study-on-the-effect-of/)
- [Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors](https://scholariq.org/papers/lanreotide-in-metastatic-enteropancreatic-neuroendocrine-tumors/)
- [Gastroenteropancreatic neuroendocrine tumours](https://scholariq.org/papers/gastroenteropancreatic-neuroendocrine-tumours/)
- [TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system](https://scholariq.org/papers/tnm-staging-of-foregut-neuro-endocrine-tumors-a-consensus-proposal-including-a/)
- [Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)](https://scholariq.org/papers/clinical-practice-guidelines-for-multiple-endocrine-neoplasia-type-1-men1/)
- [ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/enets-consensus-guidelines-update-for-the-management-of-patients-with-functional/)
- [Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours/)
- [Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastroenteropancreatic-neuroendocrine-neoplasms-esmo-clinical-practice/)
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-plus-octreotide-long-acting-repeatable-for-the-treatment-of-advanced/)
- [ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site](https://scholariq.org/papers/enets-consensus-guidelines-update-for-the-management-of-distant-metastatic/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.